loading...| Preferred Name | Pramlintide | |
| Synonyms |
PRAMLINTIDE Pramlintide Triproamylin |
|
| Definitions |
A peptide analogue of human amylin with 3 proline substitutions at positions 25, 28 and 29, with antihyperglycemic activity. By mimicking amylin, pramlintide slows gastric emptying, inhibits digestive secretions (gastric acid, pancreatic enzymes, and bile), reduces glucagon secretion, and increases satiety; all of these actions are mediated mostly by glucose-sensitive areas in the brain stem. The overall result is a decrease in blood glucose levels. The use of pramlintide may cause an increased risk of insulin-induced hypoglycemia. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C61901 |
|
| CAS_Registry |
151126-32-8 |
|
| Chemical_Formula |
C171H267N51O53S2 |
|
| code |
C61901 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 |
|
| Contributing_Source |
CTRP FDA |
|
| DEFINITION |
A peptide analogue of human amylin with 3 proline substitutions at positions 25, 28 and 29, with antihyperglycemic activity. By mimicking amylin, pramlintide slows gastric emptying, inhibits digestive secretions (gastric acid, pancreatic enzymes, and bile), reduces glucagon secretion, and increases satiety; all of these actions are mediated mostly by glucose-sensitive areas in the brain stem. The overall result is a decrease in blood glucose levels. The use of pramlintide may cause an increased risk of insulin-induced hypoglycemia. |
|
| Display_Name |
Pramlintide |
|
| FDA_UNII_Code |
D3FM8FA78T |
|
| FULL_SYN |
PRAMLINTIDE Pramlintide Triproamylin |
|
| Has_Salt_Form | ||
| label |
Pramlintide |
|
| Legacy Concept Name |
Pramlintide |
|
| NCI_Drug_Dictionary_ID |
803038 |
|
| PDQ_Closed_Trial_Search_ID |
803038 |
|
| PDQ_Open_Trial_Search_ID |
803038 |
|
| Preferred_Name |
Pramlintide |
|
| prefixIRI |
Thesaurus:C61901 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0537551 |
|
| subClassOf |